Beneficial effect of nisoldipine in repeated coronary reperfusion.
BACKGROUND
We have demonstrated that when repeated reperfusion is performed after reocclusion, there is a decrease in the amount of myocardial salvage, despite early reperfusion. It is unknown whether this deleterious effect of repeated reperfusion can be antagonized. Therefore, we studied the effect of nisoldipine (a dihydropyridine calcium antagonist) on infarct size, using a repeated-reperfusion model.


METHODS
The left anterior descending coronary artery was occluded in anaesthetized dogs. Thirty minutes after occlusion, dogs were allocated randomly to either the treatment group (n = 6; 6 micrograms/kg per min nisoldipine infused intravenously throughout the experiment) or the control group (n = 8; saline). Occlusion was maintained for 2 h, followed by 1 h of reperfusion, then 1 h of reocclusion and 2 h of second reperfusion. An in vivo area at risk was determined by gentian-violet staining, and infarct size was defined and quantitated by triphenyl-tetrazolium-chloride staining.


RESULTS
Haemodynamic measurements were similar in both groups. Mass of necrosis/mass at risk was significantly smaller in the nisoldipine group (33.3 +/- 5.8%, mean +/- SEM) compared with controls (46.8 +/- 4.8%; P < 0.05).


CONCLUSIONS
Treatment with nisoldipine induces a beneficial effect by reduction of infarct size in repeated coronary reperfusion.
Hammerman
H
H
Department of Cardiology, Rambam Medical Center, Haifa, Israel.
Moscovitz
M
M
Hir
J
J
D000818:Animals; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D003327:Coronary Disease / Q000150:complications / Q000503:physiopathology; D004195:Disease Models, Animal; D004285:Dogs; D006439:Hemodynamics / Q000187:drug effects; D007262:Infusions, Intravenous; D015428:Myocardial Reperfusion Injury / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D015737:Nisoldipine / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D011897:Random Allocation
D002121:Calcium Channel Blockers; D015737:Nisoldipine